American Association for Cancer Research Annual Meeting
AACRVenueOrlando Convention Center West
- 1/1
- Annual
- 16000㎡
- Exhibition area
- 300
- Exhibitors
- 20000
- Visitors
OrlandoBiology expo Fair Details
- Organizer:
- American Association for Cancer Research (AACR)
- City:
- United StatesOrlando
- Venue:
- Orlando Convention Center West
- Address:
- 9800 International Dr, Orlando, FL 32819美国
American Association for Cancer Research Annual MeetingProfile
The American Association for Cancer Research (AACR) Annual Meeting is one of the world’s largest and most influential oncology conferences. Each year, it draws over 20,000 participants, including cancer researchers, academics, clinicians, and industry representatives from around the globe.
The AACR serves as a critical catalyst for advancing the fight against cancer, bringing together scientists, clinicians, other healthcare professionals, survivors, patients, and advocates to share and discuss the latest breakthroughs. Covering population science and prevention; cancer biology, translational and clinical research; survivorship and advocacy, the AACR Annual Meeting showcases cutting-edge cancer science and medicine.
This year’s meeting attracted cancer scientists from across the globe, with numerous pharmaceutical companies presenting their latest research findings, including HuaSen Pharma, Yarong Pharma, and Kelun Pharmaceutical, among others.
The AACR Annual Meeting is dedicated to fostering the integration and advancement of basic research, translational science, and clinical applications in cancer prevention, diagnosis, and treatment. It addresses a wide array of topical issues spanning from fundamental research to clinical practice, spotlighting the most前沿 technologies, innovative products, and groundbreaking研究成果 in the field of oncology.
The AACR Annual Meeting is not only a premier platform for global cancer researchers to unveil major scientific achievements and exchange the latest ideas, but also a key indicator of trends and priorities in worldwide tumor research.
American Association for Cancer Research Annual Meeting tickets are e-tickets. Domestic and international visitors must complete online pre-registration with real-name passport verification. After purchase, the organizer verifies visitor identity. Visitors who do not meet entry requirements may need to submit additional documents. Once approved, you will receive email confirmation or a QR code. On site, present your original passport and confirmation letter to collect a paper badge, or scan the QR code to enter.
The Exhibition Value of the American Association for Cancer Research Annual Meeting
- The AACR Annual Meeting is the world’s largest and most authoritative academic event in cancer research. Since its inception in 1907, it has been held over a hundred times and is widely recognized in the industry as a leading indicator of global trends in cancer research and a central hub for oncology drug development. Hosted by the American Association for Cancer Research, the conference rotates annually among major U.S. cities. The 2026 meeting will take place from April 17 to 22 at the San Diego Convention Center in California, expected to attract tens of thousands of scientists, clinicians, and industry representatives from dozens of countries and regions worldwide. It serves as a vital platform for advancing the field of anti‑cancer research, offering a comprehensive showcase of cutting‑edge scientific and medical breakthroughs.
- The core value of exhibiting lies in its unparalleled academic authority and its role as a platform that precisely connects global resources for oncology R&D. The AACR Annual Meeting stands as the premier forum for scholarly exchange and the dissemination of research findings in the global cancer research community, bringing together top scientists, clinical investigators, and industry leaders from around the world each year. The program features a wide array of specialized forums and sessions, including plenary talks, thematic symposia, educational courses, and poster presentations, covering all aspects of basic science, translational medicine, clinical research, and preventive medicine. The 2026 conference will feature numerous high‑impact academic presentations on前沿 topics such as AI‑driven cancer research, mechanisms of early‑onset cancers, and innovative therapeutic approaches.
- The exhibition provides an academic exchange and commercial collaboration platform that spans the entire oncology R&D value chain. Exhibits encompass a full spectrum of products, including targeted cancer therapies, immunotherapies, antibody‑drug conjugates (ADCs), cell therapies, gene editing tools, companion diagnostics, biomarkers, experimental models, and research equipment. From fundamental scientific discoveries to clinical translation, and from early‑stage drug development to commercialization, the event fosters a complete industrial ecosystem. The 2026 conference includes educational sessions, methodological workshops, plenary discussions, and poster presentations, offering researchers, clinicians, and pharmaceutical companies a multidimensional platform for knowledge sharing.
- The exhibition aligns with three major industry trends—precision medicine, immunotherapy, and AI empowerment—establishing a technological hub where academia, industry, and clinical practice converge deeply. The 2026 conference will feature several high‑profile plenary sessions, including the opening address titled “Precision, Collaboration, Mission: Advancing Global Cancer Science to Save Lives,” as well as thematic sessions on AI‑driven cancer research, mechanisms of early‑onset cancers, and innovative treatment modalities. In addition, the program will include cutting‑edge educational courses covering CRISPR screening, protein degradation technologies, spatial omics, and other前沿 areas. By showcasing the complete innovation pipeline—from early discovery to clinical application—the conference serves as a critical window for observing and tracking global trends in cancer research.
- For Chinese enterprises, this exhibition represents a strategic gateway for expanding into global markets, connecting with international resources, and demonstrating their innovative capabilities. The 2026 AACR Annual Meeting will see active participation from numerous Chinese pharmaceutical companies. Cornerstone Pharmaceuticals has had three of its independently developed ADC candidates selected for poster presentations, including EGFR/HER3 bispecific ADCs and SSTR2/DLL3 bispecific ADCs; Asymchem has four preclinical studies chosen, focusing on innovative drugs such as orebatinib and APG‑2449. Through this internationally prestigious academic platform, Chinese companies can showcase the forefront of China’s pharmaceutical innovation, enhance their global visibility, and forge connections with worldwide research and commercial networks.
Notable exhibitors
- Biotechnology Companies:CStone Pharmaceuticals, Ascentage Pharma, biomodal,Genprex
- International Pharmaceutical Giants:Pfizer, Merck, Roche, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Eli Lilly, Amgen, Bristol-Myers Squibb, Daiichi Sankyo, Sanofi
- Leading Chinese ADC and Bispecific Antibody Companies:BeiGene, Hengrui Medicine, Innovent Biologics, Jiangsu Hengrui, CSPC Pharmaceutical Group, East China Pharmaceutical, Cansino Biologics, Yming Biologics, Bio-Thera Solutions, Duoxi Biologics, Yilian Biologics, Kexing Botai, Kanghong Pharmaceutical, Weili Zhibo, Orange Sail Pharmaceutical, Boao Xin, Lixin Pharmaceutical, Jingfang Pharmaceutical, Henlius, Rongchang Biologics, CStone Pharmaceuticals, Jinsai Pharmaceutical, Qide Pharmaceutical, Tuojie Biologics, Lepu Biologics, Qinhe Li Biologics, Hezheng Pharmaceutical, Bailisi Kang, Borui Biologics, Kangyuan Bocreat, Lianjin Biologics, Maiwei Biologics, Tuochuang Biologics, Yiming Angke
- Protein Degradation Agents and Innovative Technology Enterprises:Bio-Rad Laboratories, BioSkryb Genomics, Sino Biological, Syncell, ProteoGenix, AtaGenix (PuJian Biologics)
American Association for Cancer Research Annual Meeting Photos
AACR Exhibitor Directory / E-Magazine
American Association for Cancer Research Annual MeetingRange
Experimental Therapeutics, Molecular Targeted Therapy, Chemistry, Chemical Biology and Genetics, Immunology and Immunotherapy, Tumor Biology, Virology, Toxicology
Exhibition Review
The 2025 American Association for Cancer Research Annual Meeting (AACR Annual Meeting 2025) was successfully held in Chicago, USA, from April 25 to 30, 2025. This year’s meeting was themed “Unifying Cancer Science and Medicine: Sustaining Innovation for Transformation,” hosted by the American Association for Cancer Research, and stands as a premier annual event in the global cancer research community.
In terms of scale, the conference attracted over 22,100 registered attendees from 85 countries and regions worldwide, with more than 21,000 participants attending in person—marking a new all-time high. The program featured nearly 730 invited presentations, delivered by speakers from 30 countries, including 11 NextGen Stars—emerging scientists selected through rigorous screening. During the event, more than 200 clinical trial results were showcased, among them 15 completed Phase III trials and 9 ongoing Phase III studies, several of which hold the potential to reshape clinical practice. Over 260 scientific sessions were broadcast live online, encompassing plenary talks, specialized symposia, educational courses, and methodological workshops.
This year’s meeting was marked by numerous highlights, with Chinese contributions taking center stage. According to statistics, 111 Chinese pharmaceutical companies participated, presenting 246 innovative drug candidates, including 86 antibody–drug conjugates (ADCs), accounting for 35% of the total. In the ADC space, Chinese firms demonstrated exceptional strength—of the 157 ADCs showcased at the conference, more than half were developed by Chinese companies; furthermore, Chinese enterprises dominated among the 44 bispecific ADCs presented. Technologically, Chinese firms spearheaded several world-first innovations: Kanghong Pharmaceutical’s KH815 became the first globally approved dual‑payload ADC, simultaneously incorporating a TopoI inhibitor and an RNA polymerase II inhibitor to achieve dual DNA and RNA‑targeted cytotoxicity; Weilizhibo’s LBL‑058 was the world’s first TCE‑ADC, innovatively integrating a T‑cell engager scaffold with a cytotoxic payload. The emerging target CDH17 also made its debut on the conference’s hotspot list, emerging as a major highlight in gastrointestinal oncology; Yilian Bio’s YL217 has received FDA IND approval, becoming the first ADC targeting this biomarker to enter clinical development. During the conference, the Chinese Anti-Cancer Association held high-level discussions with AACR leadership, reviewing nearly two decades of collaborative achievements and announcing plans to sign a strategic cooperation agreement during the 2025 China Integrated Oncology Conference, further strengthening Sino‑ collaboration in cancer research.
Clinical breakthroughs and innovative therapies drew significant attention. Boehringer Ingelheim unveiled Phase III data for Zongertinib, a novel HER2‑mutant NSCLC therapy, demonstrating an objective response rate of 71%, an unprecedented level among comparable agents. GSK’s PD‑1 monoclonal antibody Jemperli achieved complete clinical remission in 84 patients with dMMR/MSI‑H locally advanced rectal cancer, with 82 of these patients remaining surgery‑free, suggesting that future cancer treatments may enable organ preservation. The T‑cell engager arena also remained highly active, with approximately 20 domestic biopharmaceutical companies showcasing cutting-edge developments: Qilu Pharmaceutical introduced the world’s first MET/EGFR/CD2/CD3 quadri‑specific TCE (QL615), which in preclinical studies outperformed other investigational products in controlling tumor growth; AstraZeneca took a different approach, developing a CD8‑guided GPC3/CD8/TCR tri‑specific TCE (AZD9793) that preferentially recruits CD8+ T cells to target tumors, effectively reducing CRS‑related cytokine production. Huaihe Bio’s CC312, the world’s first CD19/CD28/CD3 tri‑specific TCE approved for systemic lupus erythematosus IND, exhibited substantial potential in the field of autoimmune diseases.
The professional audience was exceptionally strong, with international participation reaching record levels. Over 180 accredited journalists registered for the event, with media coverage spanning top-tier outlets such as The New York Times, CNN, and NBC. On the social media platform X, the hashtag #AACR25 garnered more than 16,000 mentions, generating a total exposure of 636.6 million impressions. During the conference, AACR announced the launch of a new “Pioneer Cancer Research Grant Program,” offering nine $1 million awards for early‑stage researchers and six $1 million awards for mid‑stage investigators, totaling $15 million—setting a new record for AACR’s single grant initiative. Additionally, AACR unveiled plans to establish a Cancer Clinical Trials Center, with the first gastric‑esophageal cancer trial sponsored by AACR expected to begin patient enrollment by the end of 2025.
Attendees agreed that the AACR Annual Meeting serves not only as a premier platform for showcasing and exchanging academic advances but also as a critical hub for gaining insights into global trends in cancer research and exploring pathways toward translational medicine and precision therapeutics. The trajectory of Chinese innovative pharmaceutical companies—from “fast‑follow” to “first‑in‑class” across ADCs, TCEs, and bispecific antibodies—signals China’s emergence as a key driver of global innovation in cancer treatment.
Booth inquiry for this edition
2027 OrlandoBiology Ticket inquiry
OrlandoBiology Venue
OrlandoBiology Booth Application
Standard booth Configuration
Blank booth Configuration
Process
1.Submit the business license of the company
2.Submit product picture and name
3.Receive exhibition presentation documents and booth drawings
4.Submit booth application form/Sign booth contract
5.Pay the contract booth deposit
6.Prepare for exhibition
